Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMSA101 Safety and Efficacy Study in Advanced Solid Tumors
NCT04020185Phase 2Completed
- Sponsor
- ImmuneSensor Therapeutics
- Start
- Sep 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IMSA101 in solid tumor, sponsored by ImmuneSensor Therapeutics. Started Sep 2019; status: completed.
02
Drugs
IMSA101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04020185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04020185.